BRAIN Biotech AG appoints Johan Jansén-Storbacka as Executive Vice President of the BRAINBiocatalysts´ enzyme products business
Jansén-Storbacka succeeds Rod Sears-Black, who retired on January 1, 2025.
ZWINGENBERG, Germany, September 3, 2025 – BRAIN Biotech AG, a leading provider of integrated solutions for the biologisation of industry, has appointed Johan Jansén-Storbacka as Executive Vice President of the BRAINBiocatalysts´ enzyme products business, effective September 1, 2025.
Jansén-Storbacka succeeds Rod Sears-Black, who retired on January 1, 2025. During the interim period, BRAIN Biotech CEO Adriaan Moelker temporarily held the role and will now fully dedicate his time to leading the BRAIN Biotech Group.
With more than 20 years of experience in biotechnology, Jansén-Storbacka brings extensive expertise in enzyme applications, spanning industrial processes, animal nutrition, and home care. He holds an M.Sc. in Engineering and Management as well as an MBA.
As Executive Vice President, Jansén-Storbacka will oversee a team of around 140 employees, managing fermentation facilities in the UK and production sites in continental Europe and the US. In his new role, he will drive the BRAIN Biotech Group’s strategy to strengthen its enzyme and fermentation business and ensure a closer integration of research and production activities across the organisation.
“Johan’s broad industry background will be of great value as we continue to serve a diverse range of end markets. His extensive international experience, combined with his proven leadership skills, make him an excellent fit for the BRAINBiocatalysts´ enzyme products business.
